Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 30
- Registration Number
- NCT00292955
- Locations
- 🇺🇸
Washinton University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00291707
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study of Mitomycin C, Irinotecan, and Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00271011
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 2559
- Registration Number
- NCT00265811
- Locations
- 🇫🇷
Hopital Duffaut, Avignon, France
🇫🇷Hopital Robert Boulin, Libourne, France
🇫🇷Nouvelle Clinique Generale, Valence, France
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 940
- Registration Number
- NCT00265941
- Locations
- 🇺🇸
Billings Clinic - Downtown, Billings, Montana, United States
🇺🇸Sutter Solano Medical Center, Vallejo, California, United States
🇺🇸Cancer Care Center at John Muir Health - Concord Campus, Concord, California, United States
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 92
- Registration Number
- NCT00254137
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 247
- Registration Number
- NCT00252564
- Locations
- 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2006-10-26
- Lead Sponsor
- Trial Form Support S.L.
- Target Recruit Count
- 90
- Registration Number
- NCT00251381
- Locations
- 🇪🇸
Institut Catala Oncologia: Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸H. Josep Trueta (ICO), Girona, Spain
🇪🇸Centro Oncológico Regional de Galicia, A Coruna, Coruña, Spain
A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 82
- Registration Number
- NCT00251485
- Locations
- 🇺🇸
Veeda Oncology, Houston, Texas, United States
Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 82
- Registration Number
- NCT00251498
- Locations
- 🇺🇸
Veeda Oncology, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.